Biotech company Orphazyme, which is based in Copenhagen, Denmark, must arm itself with more patience.
On Tuesday, the company reported that it is now anticipating a final decision from the European Medicines Agency (EMA) on its leading candidate arimoclomol, meant to treat the metabolic disorder known as Niemann-Pick disease type C (NPC), in the first quarter of 2022.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.